Osteoporosemedikamente – wirken sie auf den Schmerz?

Zusammenfassung

Die Wirkung der meisten antiosteoporotischen Substanzen auf eine Schmerzreduktion ist nur unzureichend untersucht. Selbst wenn eine Schmerzlinderung beschrieben wird, bleibt unklar, ob die Schmerzlinderung in einer Verminderung der Frakturinzidenz oder in einer direkten analgetischen Wirkung begründet ist. Raloxifen hat wahrscheinlich keine direkte analgetische Wirkung. Für Kalzitonin unterstützen die in-vitro-Daten und die klinischen Daten die Hypothese einer analgetischen Wirkung nach frischen Frakturen; bei Osteoporoseschmerzen ohne frische Frakturen ist die Datenlage inkonsistent. Unter Teriparatid ist eine Schmerzlinderung dokumentiert, die aber eher nicht durch eine direkte analgetische Wirkung verursacht ist. Zu anderen Präparaten wie Strontiumranelat liegen keine Daten zur analgetischen Wirkung vor.

Summary

Data on the analgesic effect of antiosteoporotic medication are insufficient. If pain relief is reported with the use of antiosteoporotic medication the effect may be caused by a reduction in fracture incidence or by an analgesic effect.

Raloxifen seems to have no analgesic effect. In vitro data and clinical data support an analgesic effect of calcitonin in recent fractures. Data on the analgesic effect of calcitonin in osteoporotic patients without recent fractures are inconsistent. Teriparatid reduces pain but this seems not to be due to an analgesic effect. There are no data on an analgesic effect of other substances like strontium ranelate or calcium.

Schlüsselwörter

Osteoporose - Schmerz - Kalzitonin - Raloxifen

Keywords

Osteoporosis - pain - calcitonin - raloxifene

• Literatur

• 1 Arinoviche R, Arriagada M, Jacobelli S. et al. Calcitonin in acute pain due to vertebral fracture in osteoporosis. Rev Med Chil 1987; 115: 1039-1043.
• 2 Blau LA, Hoehns JD. Analgesic efficacy of calcitonin for vertebral fracture pain. Ann Pharmacother 2003; 37: 564-570.
• 3 Chesnut CH, Silverman S, Andriano K. et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis. Am J Med 2000; 109: 267-276.
• 4 Clementi G, Prato A, Conforto G, Scapagnini U. Role of serotonin in the analgesic activity of calcitonin. Eur J Pharmacol 1984; 98: 449-451.
• 5 Fabbri A, Fraioli F, Pert CB. Calcitonin receptors in the rat mesencephalon mediate its analgesic actions: autoradiographioc and behavioural analyses. Brain Res 1985; 343: 205-215.
• 6 Fillingim RB. Association between estrogen replacement therapy and back pain among postmenopausal women. Spine 2000; 27: 332-334.
• 7 Gennarri C, Chierichetti MS, Gonnelli S. et al. Migraine prophylaxis with salmon calcitonin: a cross over double blind placebo-controlled study. Headache 1986; 16: 13-16.
• 8 Gennari C. Analgesic effect of calcitonin in osteoporosis. Bone. 2002 30. 67S-70S.
• 9 Hunt S, Meißner W. Das Geschlecht als Einflussfaktor bei Schmerzstudien. Schmerz 2006; 20 (06) 80-82.
• 10 Kanis IA, Delmas P, Burckhardt P. et al. Guidelines for Diagnosis and Management of Osteoporosis” on behalf of the European Foundation for Osteoporosis an d Bone Disease. Osteoporos Int 1997; 07: 390-406.
• 11 Knopp JA, Diner BM, Blitz M. et al. Calcitonin for acute pain of osteoporotic vertebral compression fractures: a systematic review of randomised controlled trials. Osteoporosis Int 2005; 16: 1281-1290.
• 12 Kyllönen ES, Väänänen HK, Vanharanta JHV. et al. Influence of estrogen progestin treatment on back pain and disability among slim postmenopausal women with low lumbar spine bone minaral density. Spine 1999; 24: 704-708.
• 13 LeResche L, Saunders K, von Korff MR. et al. Use of exogenous hormones and risk of temporomandibular disorder pain. Pain 1997; 69: 153-160.
• 14 Mystakidou K, Befon S, Hondros K. et al. Continous subcutaneous administration of high-dose salmon calcitonin in bone metastasis. Pain control and beta-endorphin plasma levels. J Pain Symptom Manage 1999; 18: 323-330.
• 15 Nevitt MC, Chen P, Dore RK, Reginster JY. Reduced risk of low back pain following Teriparatid treatment: a meta-analysis. Osteoporosis Int 2006; 17: 273-280.
• 16 Ota N, Shibata Y, Ito H. Comparison of risedronate, calcitonin and active vitamin D treatments in postmenopausal osteoporosis. Tokyo: ASBMR; 2004: SU435.
• 17 Papadokostakis G, Katonis P, Damilakis J, Hadjipavlou A. Does raloxifene treatment influence back pain and disability among postmenopausal women with osteoporosis. European Spine Journal 2005; 14: 977-981.
• 18 Papadokostakis G. The effectiveness of calcitonin on chronic back pain and daily activities in postmenopausal women. Eur Spine J 2006; 15: 356-362.
• 19 Pecile A, Ferri S, Brage PC. et al. Effects of intracerebroventricular calcitonin in the conscious rabbit. Experientia 1975; 31: 332-333.
• 20 Peichl P, Rintelen B, Kumpan W, Broll H. Incrfease of axial and appendicular trabecular and cortical bone mineral density in established osteoporosis with intermittend nasal salmon calcitonin therapy. Gynaecol Endocrinol 1999; 13: 7-14.
• 21 Pontiroli AE, Pajetta E, Scaglia L. et al. Analgesic effect of intranasal and intramuscular salmon Calcitonin in postmenopausal osteoporosi: a double blind, double placebo study. Aging Clin Exp Res 1994; 06: 459-463.
• 22 Ringe JD. Treatment of primary osteoporosis with calcium and salmon calcitonin. Dtsch Med Wochenschr 1990; 115: 1176-1182.
• 23 Sadreddini S, Molaeefard M, Noshad H. et al. Efficacy of raloxifen in treatment of fibromyalgia in postmenopausal women. Eur J Intern Med 2008; 19: 350-355.
• 24 Scharla S, Oertel H, Helsberg K. et al. Skeletal pain in postmenopausal women with osteoporosis: prevalence and a prospective observational study of 6 months duration. Curr Med Res Opin 2006; 22: 2393-2402.
• 25 Silverman SL, Azria M. The analgesic role of calcitonin following osteoporotic fractures. Osteoporos Int 2002; 13: 858-867.
• 26 Welch SP, Cooper CW, Dewey CL. Antinociceptive activity of salmon calcitonin injected intraventricularly in mice. Modulation of morphine analgesia. Eur J Pharmacol 1992; 224: 77-82.